Litigation

Digitek (digoxin) Dosage, Symptoms and Recall

By Angel L. Reyes, III

My firm, Heygood, Orr, Reyes, Pearson & Bartolomei, is currently handling Digitek cases.  Digitek (digoxin) is the #1 choice for treating congestive heart failure and abnormal heart rhythms in the United States. On April 25, 2008, Actavis Totowa LLC, the U.S. manufacturing division of the generic pharmaceutical company Actavis Group, voluntarily initiated a Class I nationwide recall of Digitek oral tablets of all strengths. Digitek is distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label.

The voluntary recall of the Digitek tablets manufactured at the New Jersey Actavis facility occurred because tablets may have been commercially released in the U.S. market with double the thickness of the normal sized tablets. The flawed Digitek tablets may contain as much as twice the active ingredient, meaning they may have twice the strength of the recommended dosage. A double-strength tablet could cause serious digitalis toxicity, resulting in nausea, vomiting, dizziness, low blood sugar, cardiac instability, bradycardia and even death. In fact, Actavis Totowa has received numerous reports of illnesses and injuries due to patients who may have taken the double-strength tablets.

We would be pleased to assist you with your cases in any way possible.  Along those lines, I have attached a memorandum I prepared regarding Digitek.  It includes a discussion of dosage issues, typical symptoms, digoxin toxicity and what to look for in a case.  I hope it proves helpful.

Right click "save as" here to download the Digitek memorandum PDF.

©2008 Angel Reyes
www.ReyesLaw.com

Full post as published by Angel Reyes Blog on July 25, 2008 (boomark / email).